Document text
Principal Investigator: KAREN G. ANTHONY
Organization: L2 DIAGNOSTICS, LLC
Fiscal Year: 2024
Award: $299,878
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
Malaria remains one of the deadliest infectious diseases. Although much progress has been made
in the fight against malaria, a highly effective and durable vaccine is not available. New vaccine
candidates and improved delivery strategies are urgently needed. We recently demonstrated that
a Anopheles gambiae mosquito saliva protein, called AgTRIO, is a viable mRNA-LNP vaccine in
mice, either as a single agent or in synergistic combination with the target of the currently
marketed RTS,S/AS01 vaccine (Mosquirix). This project addresses the real-world problem of
delivery of an antimalaria mRNA vaccine in endemic, resource-poor countries where cold-
chain storage hugely limits deployment of mRNA vaccines. Our product solution employs
novel dissolvable microneedle patches (MNPs) to administer our AgTRIO mRNA-LNP
formulation. These microneedle patches can be self-applied, are less painful than intramuscular
injection, produce no sharps waste, have a long-term shelf life for up to six months at room
temperature, and can be produced at scale with robust methods. The single specific aim of this
project is to produce a novel AgTRIOVx MNP that protects against malaria in a mouse model in
preparation for pre-clinical and human clinical studies at a future phase.
Terms: <2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><Address><Animals><Anopheles gambiae><Anti-malarials><Biology><Bite><Blood erythrocyte><COVID-19 S protein><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><Characteristics><Clinical><Clinical Research><Clinical Study><Clinical Trials><Cold Chains><Collaborations><Communicable Diseases><Country><Culicidae><Development><Disease><Disorder><Dose><Erythrocytes><Erythrocytic><Formulation><Future><Goals><Grant><Hepatic><Human><Immune><Immune reaction><Immunes><Immunity><Immunization><Immunize><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Injections><Intramuscular><Intramuscular Injections><Laboratories><Life><Liver><Malaria><Malaria Vaccines><Malarial Vaccines><Marketing><Marrow erythrocyte><Measures><Messenger RNA><Methods><Mice><Mice Mammals><Modern Man><Mosquitoes><Murine><Mus><NIH><National Institutes of Health><Needles><Outcome><P falciparum><P. falciparum><P.falciparum><Pain><Painful><Paludism><Parasites><Phase><Plasmodium><Plasmodium Infections><Plasmodium falciparum><Population><Preparation><Preventative strategy><Prevention strategy><Preventive strategy><Printing><Proteins><RNA vaccine><RNA-based vaccine><Red Blood Cells><Red Cell><Research><Research Institute><Research Resources><Resistance development><Resistant development><Resources><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><STTR><Saliva><Salivary Gland Proteins><Salivary Proteins><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severity of illness><Small Business Technology Transfer Research><Sporozoites><Sterility><Suspension substance><Suspensions><Temperature><Time><Transmission><United States National Institutes of Health><Vaccinated><Vaccination><Vaccines><anti-malarial agents><anti-malarial drugs><blood corpuscles><circumsporozoite><circumsporozoite protein><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><cs protein><deliver mRNA><deliver messenger RNA><delivery system for mRNA><develop a vaccine><develop vaccines><developing resistance><development of a vaccine><developmental><disease severity><fighting><hepatic body system><hepatic organ system><hypodermic needle><immunogenicity><immunoreaction><improved><in vivo><intramuscular drug administration><mRNA><mRNA delivery><mRNA lipid nano particle vaccine><mRNA vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><mRNA-based vaccine><messenger RNA delivery><mouse model><murine model><new vaccines><next generation vaccines><non-human primate><nonhuman primate><novel><novel vaccines><pre-clinical><preclinical><preparations><prevent><preventing><receptor binding><receptor bound><response><spike proteins on SARS-CoV-2><sterile><thermolability><thermostability><transmission process><vaccine candidate><vaccine development><vaccine efficacy><vaccine formulation><vaccines against malaria><vector><vector mosquito><wasting>